iQure Pharma is Investment-Ready — Will Present at Keiretsu Forum Mid-Atlantic

DELAWARE, February 14, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has completed its Due Diligence process with Keiretsu Mid-Atlantic as Lead Investors, with initial commitments already secured.

Dedicated to a new generation of neuropathic pain management therapeutics, iQure developed iQ-007 as a promising candidate with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with encouraging results in neuropathic pain as well as a secondary indication of epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a better-than-standard profile in all tested in vivo pain models.

“We are delighted to have the opportunity to provide an update to the Keiretsu Mid-Atlantic and South-East Chapters,” said iQure Chief Executive Officer, Pawel Zolnierczyk. "This update helps to arrange the funding required to reach the clinical stage, which will offer alternative treatment options to a large number of patients suffering from Neuropathic Pain.”

The Due Diligence process was completed successfully, and the company is now fully prepared to accept funding from investors, while offering attractive investment terms. The Angel Investor-friendly Term Sheet for Series A Preferred offers capital protection, favorable valuation, and a significant number of warrants. Company is in the process of securing $3.9MM and first commitments have already been received from members of the Due Diligence Team.

iQure Pharma Awarded Patent for Therapy to Treat Neuropathic Pain and Epilepsy

DELAWARE, January 12, 2022 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a patent for a therapeutic being developed for the treatment of neuropathic pain and epilepsy (iQ-007). In addition, iQure’s multi-targeting compound to treat pain (iQ-008) has entered the national patent stage.

Dedicated to a new generation of neuropathic pain management therapeutics, iQure developed iQ-007 as a new chemical entity with a novel mode of action. This therapeutic has demonstrated a favorable safety profile with promising results in the secondary indication of epilepsy. iQ-008 is a rationally designed multitargeting compound which, in preclinical efficacy screenings, shows a promising profile in all in vivo pain models.

“We are delighted with this first patent granted for iQ-007,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This crucial step in the process of developing a new treatment helps to build awareness about the importance of therapies for neuropathic pain. One of the limiting factors in epilepsy and pain management treatments, like drug-resistant epilepsy, childhood epilepsy and painful diabetic peripheral neuropathy, are the debilitating central side effects limiting use in the current standard of care. Our goal is to bring relief to those populations.”

Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity often associated with epilepsy and neuropathic pain. iQ-007 has already been granted formal confirmation of patent protection by the Polish patent office.

With iQ-008 showing efficacy in outperforming standards of care, iQure is securing global protection, including the US, Europe, China and Canada. For both assets, iQure’s patents focus on composition of matter claims and medical use in neurological disorders.

Novel and promising mechanism of action for new neuropathic pain candidate iQ-007 confirmed

Delaware – November 2021, iQure Pharma Inc. (iQure), a company dedicated to the development of new pain management therapeutics, can confirm that the mechanism of action of its new neuropathic pain candidate, iQ-007, is through positive allosteric modulation (PAM) of a key glutamate neurotransporter.

iQ-007 is a promising therapeutic candidate being developed for the treatment of Neuropathic Pain and Epilepsy. iQ-007 exhibited a superior safety profile with promising efficacy results during in vivo testing.

One of the limiting factors in epilepsy and pain management treatments, like drug-resistant epilepsy, childhood epilepsy and painful diabetic peripheral neuropathy, are the debilitating central side effects limiting use in the current standard of care. Company asset iQ-007 has been extensively evaluated by prestigious the NIH ETSP program and showed a surprisingly good safety profile, while maintaining excellent and broad efficacy. Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity, often associated with epilepsy and neuropathic pain.

Pawel Zolnierczyk, Chief Executive Officer:

We are extremally glad to receive these results which substantiate previous findings with respect to efficacy and safety, where iQ-007 showed significant efficacy with virtually no side effects. As iQ-007 showed no interaction with any of the typical CNS targets, we are now confident that iQ-007 is acts not through inhibition of usual CNS pathways, but by enhancing the human body’s natural ‘safety’ system. With this unique profile, iQ-007 has tremendous opportunity to make a positive contribution to the treatment of pain, epilepsy and potentially other EAAT2 mediated diseases. We are now focused on a series of value confirming studies which will help to optimize the asset’s market positioning. We are very fortunate to be able to work with the highly respected research group led by Prof. Krzysztof Kaminski from Jagiellonian University, whose work led to the current determination of iQ-007’s mechanism of action.